Cargando…
Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
The clinical use of anti-CD40 agonist monoclonal antibodies (mAbs) is aimed at recruiting the immune system to fight the tumor cells. This approach has been demonstrated to be effective in various preclinical models. However, human CD40 Abs displayed only modest antitumor activity in cancer patients...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326085/ https://www.ncbi.nlm.nih.gov/pubmed/35911742 http://dx.doi.org/10.3389/fimmu.2022.940674 |